Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development		$ 108,707	$ 28,927	$ 689,004
General and administrative	238,758	147,608	436,958	3,911,518
Goodwill impairment	6,083,146	(0)	6,083,146	(0)
Total operating expenses	6,321,904	256,315	6,549,031	4,600,522
Loss from operations	(6,321,904)	(256,315)	(6,549,031)	(4,600,522)
Other income (expense):
Reimbursement for expenses - related party		247,492	72,246	247,492
Interest expense, net	(257,396)	(1,094,878)	(651,675)	(1,392,341)
Gain on derecognition of non-financial asset		16,951,477		16,951,477
Change in fair value of derivative on debt	(307,698)	122,919	(327,594)	(67,922)
Miscellaneous income	36,988
Loss on extinguishment / conversion of debt				(257,810)
Total other income (expense)	(528,106)	16,227,010	(907,023)	15,480,896
Net income (loss) before non-controlling interests	(6,850,010)	15,970,695	(7,456,054)	10,880,374
Net loss attributable to non-controlling interests	(93,010)	(41,424)	(173,635)	(281,964)
Net income (loss) attributable to Oncotelic Therapeutics, Inc.	$ (6,757,000)	$ 16,012,119	$ (7,282,419)	$ 11,162,338
Basic net income (loss) per share attributable to common stock	$ (0.02)	$ 0.04	$ (0.02)	$ 0.03
Basic weighted average common stock outstanding	394,374,227	379,203,841	393,829,610	378,588,600